Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
Medicus Pharma announced new Phase 1 clinical data for Teverelix, its investigational long-acting GnRH antagonist, demonstrating predictable estradiol suppression, favorable pharmacokinetics for infrequent dosing, and good safety profile. The findings support advancing Teverelix development for hormone-driven conditions including endometriosis and …